The World Health Organization (WHO) announced that it had decided, yesterday Wednesday, June 17, to stop clinical trials on hydroxychloroquine as a potential treatment of hospitalized covid-19 patients. This decision comes after concluding that this antimalartudian did not reduce the mortality rate of infected persons.
“The internal evidence provided by the Solidarity-Discavery test, the external evidence provided by the Recovery trial and the combined evidence provided by these two largely random trials, put together, suggest that hydroxychloroquine-when compared with the usual treatments of patients hospitalized for COVVI-19 These patients, ”said Ana Maria Henao Restrepo, responsible for WHO, quoted by AFP.
Covid-19 patient treatment with chloroquine of patients was suspended in all hospitals in Tunisia on May 27.
The Coronavirus Scientific Commission had justified this decision by “the decline in the number of patients with COVID-19 in hospitals”.
At the end of last March, the director general of basic health care, Chokri Hammouda had announced the launch of the use of chloroquine in the context of clinical trials aimed at treating coronavirus patients. This molecule had been administered in combination with other drugs. A number of services in Tunisian public hospitals had been authorized to use chloroquine to treat people with coronavirus.
